C11orf48 Inhibitors
SEE ALSO...
Items 1 to 10 of 17 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent kinase inhibitor that impacts various signaling pathways involving protein kinases. If C11orf48 function is regulated by phosphorylation through kinase activity, staurosporine could inhibit those kinases, leading to the decreased activity of C11orf48 by preventing its activation or modifying its interaction with other proteins. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. By inhibiting PI3K, it would decrease the activity of the AKT signaling pathway. If C11orf48 is an AKT pathway substrate or is regulated by the pathway, inhibition of PI3K would reduce AKT-mediated phosphorylation of C11orf48, leading to its functional inhibition. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX inhibits phosphodiesterases, preventing cAMP breakdown, potentially enhancing AU018091 activity through cAMP signaling. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which may enhance AU018091 if it is regulated by PKC-mediated phosphorylation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting the mTOR pathway, rapamycin could decrease the translation of proteins involved in cell growth and proliferation. If C11orf48 is involved in these processes, inhibiting mTOR could indirectly result in decreased functional activity of C11orf48 by limiting cellular resources necessary for its function. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG inhibits certain kinases, potentially reducing negative regulation on AU018091 if it is subject to kinase suppression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. Inhibition of MEK leads to decreased activation of ERK, a kinase that can regulate various transcription factors and proteins. If C11orf48 activity is downstream of ERK signaling, U0126 could reduce ERK-mediated activation or stabilization of C11orf48, hence diminishing its functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. It impedes the function of p38 MAPK, which is involved in response to stress signals and inflammatory cytokines. If C11orf48 has a role in these responses, SB203580 could indirectly inhibit the functional activity of C11orf48 by blocking the stress-activated signaling pathways that would otherwise lead to C11orf48 activation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. By inhibiting the proteasome, it prevents the degradation of misfolded or damaged proteins. If C11orf48 is involved in protein turnover or is regulated by proteasomal degradation, bortezomib could lead to an accumulation of proteins that may sequester C11orf48 or compete with it for binding partners, thus inhibiting its function. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
This compound activates sphingosine-1-phosphate receptors, potentially enhancing AU018091 if it is involved in sphingolipid signaling. | ||||||